Molecular imaging Theranostics of Neuroendocrine Tumors
- 7 January 2023
- journal article
- review article
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 53 (4) , 539-554
Abstract
No abstract availableKeywords
This publication has 109 references indexed in Scilit:
- Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?Diagnostic and Interventional Imaging, 2014
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre ExperienceJournal of Oncology, 2012
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastasesEndocrine-Related Cancer, 2011
- 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine TumorsJournal of Nuclear Medicine, 2010
- A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine TumorsJournal of Nuclear Medicine, 2009
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone ScintigraphyJournal of Nuclear Medicine, 2009
- Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine TumorsSeminars in Nuclear Medicine, 2006
- Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic TumorsJournal of Clinical Oncology, 2005